Insider Selling: EXACT Sciences Co. (NASDAQ:EXAS) Director Sells $111,895.32 in Stock

EXACT Sciences Co. (NASDAQ:EXAS) Director Katherine S. Zanotti sold 1,164 shares of the business’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $96.13, for a total transaction of $111,895.32. Following the completion of the transaction, the director now directly owns 41,907 shares in the company, valued at $4,028,519.91. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

EXAS stock opened at $94.75 on Friday. EXACT Sciences Co. has a twelve month low of $35.25 and a twelve month high of $123.31. The company has a quick ratio of 5.81, a current ratio of 6.09 and a debt-to-equity ratio of 0.64. The stock has a market cap of $14.68 billion, a P/E ratio of -89.39 and a beta of 1.89. The business’s 50-day moving average price is $90.52 and its 200-day moving average price is $81.95.

EXACT Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Thursday, July 30th. The medical research company reported ($0.58) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.04. The business had revenue of $268.87 million for the quarter, compared to the consensus estimate of $229.62 million. EXACT Sciences had a negative return on equity of 14.49% and a negative net margin of 13.65%. On average, equities research analysts expect that EXACT Sciences Co. will post -1.63 earnings per share for the current fiscal year.

Several equities research analysts have commented on EXAS shares. Craig Hallum dropped their price objective on shares of EXACT Sciences from $99.00 to $92.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. SVB Leerink upped their price objective on shares of EXACT Sciences from $90.00 to $115.00 and gave the company an “outperform” rating in a report on Friday. Bank of America upped their price objective on shares of EXACT Sciences from $88.00 to $94.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Robert W. Baird upped their price objective on shares of EXACT Sciences from $90.00 to $92.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Finally, ValuEngine downgraded shares of EXACT Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, April 17th. Eighteen investment analysts have rated the stock with a buy rating, EXACT Sciences has an average rating of “Buy” and a consensus price target of $105.80.

A number of institutional investors have recently made changes to their positions in EXAS. Parallel Advisors LLC boosted its position in EXACT Sciences by 13.5% during the second quarter. Parallel Advisors LLC now owns 901 shares of the medical research company’s stock worth $78,000 after purchasing an additional 107 shares in the last quarter. CSat Investment Advisory L.P. lifted its position in shares of EXACT Sciences by 18.8% in the first quarter. CSat Investment Advisory L.P. now owns 826 shares of the medical research company’s stock valued at $48,000 after acquiring an additional 131 shares in the last quarter. Curbstone Financial Management Corp lifted its position in shares of EXACT Sciences by 0.7% in the second quarter. Curbstone Financial Management Corp now owns 21,150 shares of the medical research company’s stock valued at $1,839,000 after acquiring an additional 150 shares in the last quarter. Beech Hill Advisors Inc. lifted its position in shares of EXACT Sciences by 0.6% in the second quarter. Beech Hill Advisors Inc. now owns 28,710 shares of the medical research company’s stock valued at $2,496,000 after acquiring an additional 175 shares in the last quarter. Finally, Verus Capital Partners LLC lifted its position in shares of EXACT Sciences by 40.7% in the first quarter. Verus Capital Partners LLC now owns 691 shares of the medical research company’s stock valued at $40,000 after acquiring an additional 200 shares in the last quarter. 86.66% of the stock is currently owned by institutional investors.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Featured Story: Why is insider trading harmful?

Insider Buying and Selling by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.